Daniel W Jones1, Donald C Clark2. 1. Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA. djones@umc.edu. 2. Department of Medicine, Division of Cardiology, University of Mississippi Medical Center, Jackson, MS, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to describe the long-term or lifetime relationship between blood pressure and target organ damage. The use of the term "blood pressure" as opposed to hypertension is purposeful. The risk of cardiovascular disease from blood pressure begins below the levels of blood pressure defined as hypertension by contemporary definitions. RECENT FINDINGS: An important recent publication that bears on this topic was the 2017 ACC/AHA Blood Pressure Management Guidelines. The redefinition of hypertension and blood pressure treatment goal to 130/80 mmHg and the decision to rely almost exclusively on data from event-based randomized controlled clinical trials, which led to a recommendation for lifestyle therapy only for most with stage 1 hypertension, were important. A report from the CARDIA study demonstrated significant risk for cardiovascular disease at 20 years for stage 1 hypertension. Based on all evidence, clinicians should consider the use of medication for stage 1 hypertension in those uncontrolled on lifestyle therapy.
PURPOSE OF REVIEW: The purpose of this review is to describe the long-term or lifetime relationship between blood pressure and target organ damage. The use of the term "blood pressure" as opposed to hypertension is purposeful. The risk of cardiovascular disease from blood pressure begins below the levels of blood pressure defined as hypertension by contemporary definitions. RECENT FINDINGS: An important recent publication that bears on this topic was the 2017 ACC/AHA Blood Pressure Management Guidelines. The redefinition of hypertension and blood pressure treatment goal to 130/80 mmHg and the decision to rely almost exclusively on data from event-based randomized controlled clinical trials, which led to a recommendation for lifestyle therapy only for most with stage 1 hypertension, were important. A report from the CARDIA study demonstrated significant risk for cardiovascular disease at 20 years for stage 1 hypertension. Based on all evidence, clinicians should consider the use of medication for stage 1 hypertension in those uncontrolled on lifestyle therapy.
Authors: Shezel Muneer; Ikechi G Okpechi; Feng Ye; Deenaz Zaidi; Mohammed M Tinwala; Laura N Hamonic; Anukul Ghimire; Naima Sultana; Dan Slabu; Maryam Khan; Branko Braam; Kailash Jindal; Scott Klarenbach; Raj Padwal; Jennifer Ringrose; Nairne Scott-Douglas; Soroush Shojai; Stephanie Thompson; Aminu K Bello Journal: Can J Kidney Health Dis Date: 2022-06-21